<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <id>https://recalls.watch/feed/substance-prazosin.xml</id>
  <title>Recalls Watch: Prazosin</title>
  <link rel="self" href="https://recalls.watch/feed/substance-prazosin.xml"/>
  <link href="https://recalls.watch/alerts/"/>
  <updated>2026-04-08T00:00:00Z</updated>
  <entry>
    <id>https://recalls.watch/recall/fda/98658/</id>
    <title>Appco Pharma LLC: Prazosin Hydrochloride Capsules and 2 more</title>
    <link href="https://recalls.watch/recall/fda/98658/"/>
    <updated>2026-04-08T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/97826/</id>
    <title>Amerisource Health Services LLC: Prazosin Hydrochloride and 2 more</title>
    <link href="https://recalls.watch/recall/fda/97826/"/>
    <updated>2025-11-05T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/97755/</id>
    <title>Teva Pharmaceuticals USA, Inc: Prazosin Hydrochloride and 2 more</title>
    <link href="https://recalls.watch/recall/fda/97755/"/>
    <updated>2025-11-05T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.</summary>
  </entry>
</feed>
